News

The approval marks the first and only of its kind, with the treatment anticipated to be commercially available by prescription in the US sometime in Q1 of 2019.

A recent review of treatments for pediatric status epilepticus included a critical assessment of non-medicinals which detailed that the evidence for their use is mostly anecdotal.

The approval adds medication-refractory tremor from Parkinson disease to the current indication for incisionless, focused ultrasound thalamotomy.

Neurology News Network for the week of December 22, 2018.

The principal research scientist at Neuroscience Research Australia and an associate professor of medicine at the University of New South Wales provided more insight into the latest knowledge regarding sleep apnea phenotyping and its role in the development of targeted pharmacotherapies.

Although the therapy did not achieve significance for the primary end point in the full data set, a pre-specified exploratory analysis implemented in a post-hoc framework did provide evidence of significant benefit for the 20-μg dose.

With more than a dozen disease-modifying therapies, some have set their sights on developing an agent designed to promote remyelination.

The results of the study found that those taking IRL790 had a mean reduction of 8.2% in dyskinesia scores compared to placebo.

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine explained how an increase in the number of MS neurologists could improve the state of care.

The trial of the mesenchymal stem cells therapy is expected to commence in early 2019.

Although telestroke programs show more success in bringing stroke care to patients, lingering challenges have prevented widespread implementation.

Patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days for both monthly and quarterly dosing regimens.

After failing to show motor symptom improvement in patients with Huntington disease in several clinical trials, pridopidine may have hit the end of its developmental road.

Growing enthusiasm in the Parkinson disease research community largely centers on advances in understanding the genetic underpinnings of the disease.

Bayer’s pharmacovigilance database showed a similar rate of birth defects and spontaneous abortions in those exposed to IFN-β in comparison with available general population worldwide estimates.

The professor of neurology at the Hospital of the University of Pennsylvania and the chief of the Multiple Sclerosis Division at the Perelman School of Medicine spoke about this strategy and why it came to be.

The Director of the Cleveland Clinic Epilepsy Center spoke about how important it is for clinicians to not select the wrong patients for deep brain stimulation.

The treatment is the first approved novel, oral once-daily extended release formulation of oxcarbazepine for the treatment of partial-onset seizures in patients aged 6 years and older.

If approved, diroximel fumarate may offer a differentiated gastrointestinal tolerability profile for patients with relapsing forms of multiple sclerosis.

Based on the findings, patients who are stable on their current IFN-ß therapy should remain on that therapy, but further studies are needed on when to switch therapies in multiple sclerosis.

The professor and head of the Department of Neurology and Rehabilitation at the University of Illinois at Chicago spoke about how data can better inform epilepsy care.

The epileptologist at the University of Pennsylvania spoke about the multiple options for patients with epilepsy and the need for a better understanding of choosing from the options.

The treatment, previously known as retigabine, was assessed in a phase 2 trial in more than 60 patients with amyotrophic lateral sclerosis.

Neurology News Network for the week of December 15, 2018.

Although the trial was small, the findings reiterate what has previously been shown with natalizumab in larger, prior studies.

The study found 33 additional single nucleotide polymorphisms with stronger relationships with a single subgroup.

Physicians have debated whether or not cognition is a reliable marker for disease deterioration, and if it should necessitate a change in therapy.

What is the most common risk factor for Guillain-Barré Syndrome? Plus 4 other quick questions to test your knowledge. 

The trial results indicate that EBV-specific adoptive T cell therapy is well tolerated and further back this approach in efficacy trials.

A new analysis has suggested that an inflammatory response may be a crucial and modifiable determinant of disability accrual in progressive-onset multiple sclerosis.